Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-06-24 Declaration of Voting R…
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 23, 2021, by Cidara Therapeutics, Inc. The content focuses on the submission of matters to a vote of security holders at the 2021 Annual Meeting of Stockholders, including election of directors, ratification of the independent auditor, and advisory votes on executive compensation. The document provides detailed voting results for each proposal. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document is not an annual report, earnings release, or proxy statement, but specifically reports voting outcomes. The length is just over 5,000 characters, and the content is substantive, not merely an announcement or certification. Therefore, the correct classification is DVA with high confidence.
2021-06-24 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a specific event: receipt of an upfront payment under a license and collaboration agreement, and the expiration of the Hart-Scott-Rodino waiting period. There are no financial statements or detailed financial analysis present, only an event disclosure. The document length is 3087 characters, which is relatively short and consistent with an event announcement rather than a full report. This fits the definition of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into other specific categories. It is not an Annual Report, Earnings Release, or Capital Update, but rather a current event disclosure in an 8-K form.
2021-05-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 13, 2021. It announces the issuance of a press release reporting financial results for the first quarter ended March 31, 2021. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length is 3692 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release itself. Therefore, the document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit the other more specific categories like Earnings Release (ER) or Interim Report (IR).
2021-05-13 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q1 2021
2021-05-13 English
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document is identified as 'DEFA14A' and contains 'Definitive Additional Materials' related to a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The presence of 'Schedule 14A' and terms like 'Proxy Statement' indicate this is related to shareholder voting materials. The document is not the proxy statement itself but additional definitive materials related to it. This matches the description of Remuneration Information filings or Proxy Solicitation & Information Statement filings. However, since it is definitive additional materials to a proxy statement, the best fit is 'DEF 14A' which covers reports detailing compensation and proxy materials. The document length is short and it is not a full report but additional materials, so it is not a full Annual Report or Management Report. Therefore, the classification is 'DEF 14A' with high confidence.
2021-04-28 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2021-04-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.